Prolonged phorbol ester treatment down-regulates protein kinase C isozymes and increases contraction rate in neonatal cardiac myocytes

John A. Johnson, Sudeshna Adak, Daria Mochly-Rosen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We have determined the effects of chronic exposure to the protein kinase C (PKC) activating drug 4-p phorbol 12-myristate-13-acetate (PMA) on PKC isozymes and the rate of spontaneous contraction in neonatal rat cardiac myocytes in culture. Western blot analyses revealed that a two day exposure to 0.1-1 nM PMA increased the total amount of δPKC, whereas, 100 nM PMA concentrations caused a complete down-regulation of the αPKC and an 80 kDa ζPKC-like protein. In addition, 100 nM PMA treatment for 2 days did not result in complete down-regulation of the β, 6, and εPKC isozymes in Western blot and immunocytochemical studies. We also found a PKC-mediated enhancement of the rate of contraction in these cells following prolonged exposure to PMA (1-100nM). Our studies suggest that this enhancement of contraction rate may be mediated by the β, δ, or εPKC isozymes. A better understanding of the role(s) of PKC isozymes in the modulation of cardiac functions may reveal selective targets for therapies of cardiac disorders.

Original languageEnglish (US)
Pages (from-to)1027-1038
Number of pages12
JournalLife sciences
Volume57
Issue number11
DOIs
StatePublished - Aug 4 1995

Fingerprint

Phorbol Esters
Cardiac Myocytes
Protein Kinase C
Isoenzymes
Down-Regulation
Acetates
Western Blotting
Rats
Modulation
phorbol-12-myristate

Keywords

  • PKC isozymes
  • cardiac myocyte
  • contraction rate
  • phorbol ester

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Prolonged phorbol ester treatment down-regulates protein kinase C isozymes and increases contraction rate in neonatal cardiac myocytes. / Johnson, John A.; Adak, Sudeshna; Mochly-Rosen, Daria.

In: Life sciences, Vol. 57, No. 11, 04.08.1995, p. 1027-1038.

Research output: Contribution to journalArticle

@article{cfa680ebe6634237acc1bde26c28d284,
title = "Prolonged phorbol ester treatment down-regulates protein kinase C isozymes and increases contraction rate in neonatal cardiac myocytes",
abstract = "We have determined the effects of chronic exposure to the protein kinase C (PKC) activating drug 4-p phorbol 12-myristate-13-acetate (PMA) on PKC isozymes and the rate of spontaneous contraction in neonatal rat cardiac myocytes in culture. Western blot analyses revealed that a two day exposure to 0.1-1 nM PMA increased the total amount of δPKC, whereas, 100 nM PMA concentrations caused a complete down-regulation of the αPKC and an 80 kDa ζPKC-like protein. In addition, 100 nM PMA treatment for 2 days did not result in complete down-regulation of the β, 6, and εPKC isozymes in Western blot and immunocytochemical studies. We also found a PKC-mediated enhancement of the rate of contraction in these cells following prolonged exposure to PMA (1-100nM). Our studies suggest that this enhancement of contraction rate may be mediated by the β, δ, or εPKC isozymes. A better understanding of the role(s) of PKC isozymes in the modulation of cardiac functions may reveal selective targets for therapies of cardiac disorders.",
keywords = "PKC isozymes, cardiac myocyte, contraction rate, phorbol ester",
author = "Johnson, {John A.} and Sudeshna Adak and Daria Mochly-Rosen",
year = "1995",
month = "8",
day = "4",
doi = "10.1016/0024-3205(95)02048-N",
language = "English (US)",
volume = "57",
pages = "1027--1038",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Prolonged phorbol ester treatment down-regulates protein kinase C isozymes and increases contraction rate in neonatal cardiac myocytes

AU - Johnson, John A.

AU - Adak, Sudeshna

AU - Mochly-Rosen, Daria

PY - 1995/8/4

Y1 - 1995/8/4

N2 - We have determined the effects of chronic exposure to the protein kinase C (PKC) activating drug 4-p phorbol 12-myristate-13-acetate (PMA) on PKC isozymes and the rate of spontaneous contraction in neonatal rat cardiac myocytes in culture. Western blot analyses revealed that a two day exposure to 0.1-1 nM PMA increased the total amount of δPKC, whereas, 100 nM PMA concentrations caused a complete down-regulation of the αPKC and an 80 kDa ζPKC-like protein. In addition, 100 nM PMA treatment for 2 days did not result in complete down-regulation of the β, 6, and εPKC isozymes in Western blot and immunocytochemical studies. We also found a PKC-mediated enhancement of the rate of contraction in these cells following prolonged exposure to PMA (1-100nM). Our studies suggest that this enhancement of contraction rate may be mediated by the β, δ, or εPKC isozymes. A better understanding of the role(s) of PKC isozymes in the modulation of cardiac functions may reveal selective targets for therapies of cardiac disorders.

AB - We have determined the effects of chronic exposure to the protein kinase C (PKC) activating drug 4-p phorbol 12-myristate-13-acetate (PMA) on PKC isozymes and the rate of spontaneous contraction in neonatal rat cardiac myocytes in culture. Western blot analyses revealed that a two day exposure to 0.1-1 nM PMA increased the total amount of δPKC, whereas, 100 nM PMA concentrations caused a complete down-regulation of the αPKC and an 80 kDa ζPKC-like protein. In addition, 100 nM PMA treatment for 2 days did not result in complete down-regulation of the β, 6, and εPKC isozymes in Western blot and immunocytochemical studies. We also found a PKC-mediated enhancement of the rate of contraction in these cells following prolonged exposure to PMA (1-100nM). Our studies suggest that this enhancement of contraction rate may be mediated by the β, δ, or εPKC isozymes. A better understanding of the role(s) of PKC isozymes in the modulation of cardiac functions may reveal selective targets for therapies of cardiac disorders.

KW - PKC isozymes

KW - cardiac myocyte

KW - contraction rate

KW - phorbol ester

UR - http://www.scopus.com/inward/record.url?scp=0029164556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029164556&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(95)02048-N

DO - 10.1016/0024-3205(95)02048-N

M3 - Article

C2 - 7658910

AN - SCOPUS:0029164556

VL - 57

SP - 1027

EP - 1038

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 11

ER -